fludarabine has been researched along with cyc 202 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD | 1 |
| Błoński, JZ; Góralski, P; Kiliańska, ZM; Komina, O; Piekarski, H; Robak, T; Rogalińska, M; Wesierska-Gadek, J; Zołnierczyk, JD | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD | 1 |
3 other study(ies) available for fludarabine and cyc 202
| Article | Year |
|---|---|
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine | 2009 |
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Survival; Cells, Cultured; Cladribine; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Purines; Roscovitine; Vidarabine | 2010 |
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine | 2012 |